

Datasheet: HCA216 BATCH NUMBER 168787

HUMAN ANTI INFLIXIMAB
INFLIXIMAB
REMICADE [®]
Purified
Monoclonal Antibody
AbD19376_hlgG1
lgG1
0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA				

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody selected from the HuCAL phage display library and expressed in a human cell line.
Preparation	Purified IgG prepared by affinity chromatography on Protein A.
Source	HKB-11
Buffer Solution	Phosphate buffered saline

Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml.
Immunogen	Infliximab

Specificity

Human anti Infliximab, clone AbD19376_hlgG1, is an anti-idiotypic antibody that binds to both free infliximab and to infliximab bound to its target, TNF α . Clone AbD19376_hlgG1 does not inhibit the binding of infliximab to TNF α . It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.

Clone AbD19376_hlgG1 binds to an epitope outside the infliximab binding site. This epitope is shared with other chimeric antibodies that are highly homologous to infliximab including the chimeric antibody cetuximab but not rituximab.

Human anti Infliximab, clone AbD19376_hIgG1 is a fully human antibody and may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera. In the HRP-conjugated format, clone AbD19376_IgG1 is suitable as a detection antibody in pharmacokinetic (PK) assays to measure total infliximab levels (free drug, partially bound and fully bound).

Infliximab (branded as Remicade®) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.

Infliximab is directed against Tumor Necrosis Factor Alpha (TNF α) and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNF α expressing T-lymphocytes.

View a summary of all anti-infliximab antibodies.

Affinity

The monovalent intrinsic affinity of this antibody was measured as $K_D=0.7$ nM by real time, label-free molecular interaction analysis on immobilized inifliximab.

ELISA

This product may be used in a direct ELISA, as a bridging antibody in ADA assays or as a detection antibody in an Infliximab bridging ELISA when conjugated to HRP together with HCA212 or HCA214 as the capture reagent.

Protocol: PK bridging ELISA to measure total drug

Protocol: ADA bridging ELISA

References

1. Kashiwagi, N. *et al.* (0) Method for measuring anti-drug antibody <u>US Patent Application</u> <u>US2017315118A1</u>

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee

12 months from date of despatch.

Acknowledgements

This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and

non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details. Remicade is a registered trademark of Janssen Biotech Inc. Inflectra is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp. **Health And Safety** Material Safety Datasheet documentation #10040 available at: Information https://www.bio-rad-antibodies.com/SDS/HCA216 10040 **Licensed Use** For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad. Regulatory For research purposes only. **Technical Advice** Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Useful Reagents

RECOMBINANT HUMAN TNF ALPHA (PHP051)

MOUSE ANTI HUMAN IgG (Fc) CH2 DOMAIN:HRP (MCA647P)

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK002P)

HUMAN ANTI INFLIXIMAB (HCA212)

HUMAN ANTI INFLIXIMAB (HCA214)

HUMAN ANTI INFLIXIMAB (HCA215)

HUMAN ANTI INFLIXIMAB (HCA213)

HISPEC ASSAY DILUENT (BUF049A)

North & South Tel: +1 800 265 7376 America Fax: +1 919 878 3751 Worldwide Tel

Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M430482:240510'

Printed on 29 Aug 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint

Email: antibody_sales_us@bio-rad.com